Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Acquired by Morse Asset Management Inc

Morse Asset Management Inc boosted its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.0% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 13,112 shares of the medical research company’s stock after purchasing an additional 259 shares during the period. Thermo Fisher Scientific makes up about 1.9% of Morse Asset Management Inc’s portfolio, making the stock its 12th largest holding. Morse Asset Management Inc’s holdings in Thermo Fisher Scientific were worth $7,621,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its position in Thermo Fisher Scientific by 0.4% in the first quarter. Vanguard Group Inc. now owns 33,095,791 shares of the medical research company’s stock worth $19,235,605,000 after purchasing an additional 117,353 shares during the period. Capital World Investors lifted its position in Thermo Fisher Scientific by 10.0% in the first quarter. Capital World Investors now owns 13,493,852 shares of the medical research company’s stock worth $7,842,762,000 after purchasing an additional 1,231,059 shares during the period. Price T Rowe Associates Inc. MD lifted its position in shares of Thermo Fisher Scientific by 1.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 10,054,621 shares of the medical research company’s stock valued at $5,843,848,000 after acquiring an additional 156,675 shares during the last quarter. Capital Research Global Investors lifted its position in shares of Thermo Fisher Scientific by 1.5% during the 1st quarter. Capital Research Global Investors now owns 8,113,137 shares of the medical research company’s stock valued at $4,715,436,000 after acquiring an additional 123,523 shares during the last quarter. Finally, Norges Bank acquired a new stake in shares of Thermo Fisher Scientific during the 4th quarter valued at $2,909,524,000. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the company. Raymond James increased their price objective on Thermo Fisher Scientific from $650.00 to $660.00 and gave the company an “outperform” rating in a research report on Thursday. Stifel Nicolaus boosted their target price on shares of Thermo Fisher Scientific from $600.00 to $615.00 and gave the company a “buy” rating in a research note on Thursday. Deutsche Bank Aktiengesellschaft upped their price target on shares of Thermo Fisher Scientific from $600.00 to $610.00 and gave the stock a “buy” rating in a research note on Thursday, April 25th. The Goldman Sachs Group upped their price target on shares of Thermo Fisher Scientific from $550.00 to $640.00 and gave the stock a “buy” rating in a research note on Wednesday, April 10th. Finally, Robert W. Baird upped their price target on shares of Thermo Fisher Scientific from $620.00 to $632.00 and gave the stock an “outperform” rating in a research note on Thursday. Five analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $618.94.

Thermo Fisher Scientific Stock Performance

TMO stock traded up $12.64 during mid-day trading on Friday, reaching $607.14. 2,715,365 shares of the stock traded hands, compared to its average volume of 1,737,231. Thermo Fisher Scientific Inc. has a 52 week low of $415.60 and a 52 week high of $614.65. The company has a quick ratio of 1.33, a current ratio of 1.72 and a debt-to-equity ratio of 0.64. The firm has a market capitalization of $231.76 billion, a PE ratio of 38.94, a P/E/G ratio of 2.83 and a beta of 0.77. The business has a 50-day moving average of $563.01 and a two-hundred day moving average of $565.97.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, July 24th. The medical research company reported $5.37 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.13 by $0.24. Thermo Fisher Scientific had a net margin of 14.69% and a return on equity of 18.22%. The firm had revenue of $10.54 billion during the quarter, compared to analyst estimates of $10.50 billion. During the same quarter in the prior year, the business posted $5.15 earnings per share. The company’s quarterly revenue was down 1.4% compared to the same quarter last year. As a group, equities analysts predict that Thermo Fisher Scientific Inc. will post 21.69 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, October 15th. Investors of record on Friday, September 13th will be given a $0.39 dividend. This represents a $1.56 annualized dividend and a yield of 0.26%. The ex-dividend date is Friday, September 13th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.01%.

Insider Buying and Selling

In other news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $567.28, for a total transaction of $5,672,800.00. Following the completion of the sale, the chief executive officer now owns 123,816 shares of the company’s stock, valued at $70,238,340.48. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.